Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $15.00 target price on the stock. D. Boral Capital’s price objective would suggest a potential upside of 123.88% from the stock’s current price.

COYA has been the subject of a number of other research reports. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, February 6th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday, November 11th.

Coya Therapeutics Stock Up 2.4 %

NASDAQ COYA opened at $6.70 on Monday. The firm has a market cap of $111.94 million, a price-to-earnings ratio of -10.31 and a beta of 0.31. The business has a 50-day moving average price of $6.24 and a 200-day moving average price of $6.46. Coya Therapeutics has a twelve month low of $4.75 and a twelve month high of $10.69.

Hedge Funds Weigh In On Coya Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp boosted its stake in Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after buying an additional 3,099 shares during the last quarter. Geode Capital Management LLC boosted its stake in Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after buying an additional 4,485 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Coya Therapeutics by 1,005.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after buying an additional 4,777 shares during the last quarter. XTX Topco Ltd purchased a new stake in Coya Therapeutics during the fourth quarter valued at approximately $59,000. Finally, Jane Street Group LLC purchased a new stake in Coya Therapeutics during the fourth quarter valued at approximately $74,000. 39.75% of the stock is owned by institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.